ALAB shows strong balance sheet expansion with assets growing 45% to $1.5B, though liabilities increased substantially and R&D expenses grew meaningfully.
The company appears to be in a growth investment phase, with substantial increases in R&D spending alongside meaningful balance sheet expansion. The notable increase in total liabilities, while accompanied by strong stockholders' equity growth, suggests either debt-financed expansion or increased operational obligations that warrant monitoring.
ALAB's financial position expanded significantly with total assets reaching $1.5B (up 45%) and stockholders' equity growing 41% to $1.4B, indicating strong capitalization. However, total liabilities increased substantially to $168M, and R&D expenses grew meaningfully to $304M, suggesting aggressive investment in development activities. The overall picture signals a company in active growth mode with strong equity backing but elevated spending and liability levels.
Liabilities grew 87.5% — significant increase in debt or obligations, assess impact on financial flexibility.
Current liabilities surged 53.7% — significant near-term obligations; verify ability to meet short-term debt.
R&D investment increased 51.4% — signals commitment to future product development, though near-term margin impact.
Asset base grew 45.3% — expansion through organic growth, acquisitions, or capital deployment.
Equity base grew 41.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Inventory surged 36.5% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.
Current assets grew 34.5% — improving short-term liquidity or inventory/receivables build.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →